Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

Impact of Allogeneic Hematopoietic Cell Transplantation Post-Sars-Cov-2 Infection: A Retrospective Analysis By the German Cooperative Transplant Study Group

Blood (2024) 144 (Supplement 1): 3554.

https://doi.org/10.1182/blood-2024-204560

Published: 2024

Journal Articles

Allogeneic Stem Cell Transplantation in Patients Aged ≥70 Years: Epidemiology, Outcomes, and Risk Factors Based on the German Registry for Stem Cell Transplantation (DRST)

Blood (2021) 138 (Supplement 1): 3926.

https://doi.org/10.1182/blood-2021-152349

Published: 2021

Journal Articles

Post-Transplant MRD Negativity on Day +100 Predicts Outcomes for Pre-Transplant Relapsed/Refractory AML Patients

Evgeny Klyuchnikov, Anita Badbaran, Radwan Massoud, Ulrike Fritsche-Friedland, Maximilian Christopeit, Dietlinde Janson, Francis A. Ayuk, Christine Wolschke, Nicolaus Kröger

Blood (2021) 138 (Supplement 1): 4909.

https://doi.org/10.1182/blood-2021-152148

Published: 2021

Journal Articles

Treatment of MDS, AML and CMML Relapse after Allogeneic Blood Stem Cell Transplantation with Azacitidine, Lenalidomide and Donor Lymphocyte Infusions - Final Results of the Prospective Azalena-Trial (NCT02472691)

Thomas Schroeder, Matthias Stelljes, Maximilian Christopeit, Eva Schmidt, Christoph Scheid, Jan-Henrik Mikesch, Christina Rautenberg, Paul Jäger, Nadja Drusenheimer, Udo Holtick, Stefan Klein, Rudolf Trenschel, Rainer Haas, Ulrich Germing, Nicolaus Kröger, Guido Kobbe

Blood (2021) 138 (Supplement 1): 411.

https://doi.org/10.1182/blood-2021-153282

Published: 2021

Journal Articles

Clinical Relevance of Somatic Mutations in Chronic Myelomonocytic Leukemia Undergoing Allogeneic Stem Cell Transplantation

Nico Gagelmann, Anita Badbaran, Rashit Bogdanov, PhD, Olivier Nibourel, Friedrich Stoelzel, MD, Christina Rautenberg, MD, Heiko Becker, MD, Aleksandar Radujkovic, MD, Michael Koldehoff, Prof, MD PhD, Maximilian Christopeit, PhD, Peter Dreger, Jürgen Finke, MD, Guido Kobbe, MD, Uwe Platzbecker, Marie Robin, MD, Dietrich W. Beelen, Nicolaus Kroeger, MD

Blood (2019) 134 (Supplement_1): 1713.

https://doi.org/10.1182/blood-2019-121969

Published: 2019

Journal Articles

High Cure Rate By Allogeneic Stem Cell Transplantation for Myelofibrosis Patients Aged 65 or Older

Giulia Daghia, MD PhD, Tatjana Zabelina, MD, Gaby Zeck, Ute-Marie von Pein, MD, Maximilian Christopeit, MD, Christine Wolschke, MD, Francis Ayuketang Ayuk, MD, Nicolaus Kroeger, MD

Blood (2018) 132 (Supplement 1): 4637.

https://doi.org/10.1182/blood-2018-99-113255

Published: 2018

Journal Articles

Clonal Evolution of Myelofibrosis Patients in Relapse after Allogeneic Stem Cell Transplantation Revealed By Whole Exome Sequencing

Maximilian Christopeit, MD, Anita Badbaran, Malik Alawi, M. Sc., Christine Wolschke, Francis A Ayuk, Nicolaus Kröger

Blood (2017) 130 (Supplement 1): 2912.

https://doi.org/10.1182/blood.V130.Suppl_1.2912.2912

Published: 2017

Journal Articles

Allogeneic Stem Cell Transplantation As Salvage Therapy for First Relapse after Autografting in Multiple Myeloma Patients

Evgeny Klyuchnikov, MD, Christine Wolschke, MD, Anita Badbaran, Maximilian Christopeit, MD, Ute-Marie von Pein, MD, Francis A. Ayuk, MD, Nicolaus Kröger, MD

Blood (2016) 128 (22): 4619.

https://doi.org/10.1182/blood.V128.22.4619.4619

Published: 2016

Journal Articles

Ruxolitinib for Myelofibrosis Patients Relapsing after Allogeneic Hematopoietic Transplantation

Dietlinde Janson, MD, Francis A Ayuk, MD, Christine Wolschke, MD, Maximilian Christopeit, MD, Anita Badbaran, Ute-Marie von Pein, MD, Andre van Randenborgh, MD, Nicolaus Kroeger, MD

Blood (2016) 128 (22): 1948.

https://doi.org/10.1182/blood.V128.22.1948.1948

Published: 2016

Journal Articles

Ruxolitinib during Peritransplant Period for Myelofibrosis Patients Undergoing Allogeneic Stem Cell Transplantation Reduces Acute Graft-Versus-Host Disease

Nicolaus Kröger, MD, Sharifah Shahnaz Syed Abd Kadir, MD, Tatjana Zabelina, MD, Christine Wolschke, MD, Francis A. Ayuk, MD, Anita Badbaran, Maximilian Christopeit, MD

Blood (2016) 128 (22): 2242.

https://doi.org/10.1182/blood.V128.22.2242.2242

Published: 2016

Journal Articles

Impact of Pre-Transplant Ruxolitinib in Myelofibrosis Patients on Outcome after Allogeneic Stem Cell Transplantation

Sharifah Shahnaz Syed Abd Kadir, MD, Tatjana Zabelina, MD, Maximilian Christopeit, MD, Gerald G Wulf, MD, Eva Maria Wagner, MD, Martin Bornhäuser, MD, Thomas Schroeder, MD, Martina Crysandt, MD, Karin Mayer, MD, Matthias Stelljes, Anita Badbaran, Christine Wolschke, MD, Francis A. Ayuk, MD, Ioanna N Triviai, PhD, Dominik Wolf, MD, Nicolaus Kröger, MD

Blood (2016) 128 (22): 1950.

https://doi.org/10.1182/blood.V128.22.1950.1950

Published: 2016

Journal Articles

Impact of Donor-Recipient Histocompatibility and CMV-Mismatch on Outcome of Allogeneic Stem Cell Transplantation for AML and MDS: A Retrospective Registry Study of the German Stem Cell Transplant Registry (DRST) of the German Working Group for Blood and Marrow Transplantation (DAG-KBT)

Francis A. Ayuk, MD, Dietrich W. Beelen, Prof. Dr. MD, Martin Bornhäuser, MD, Matthias Stelljes, Tajana Zabelina, MD, Jürgen Finke, Guido Kobbe, MD, Daniel Wolff, MD, Eva Maria Wagner, MD, Maximilian Christopeit, MD, Christoph Schmid, MD, Hellmut Ottinger, MD, Christoph Groth, MD, Christoph Faul, MD, Hartmut Bertz, MD, Elena Rachlis, MD, Christine Wolschke, MD, Nicolaus Kröger, MD, Wolfgang Bethge, MD

Blood (2016) 128 (22): 2304.

https://doi.org/10.1182/blood.V128.22.2304.2304

Published: 2016

Journal Articles

Daratumumab Is an Effective and Safe Salvage Therapy in Relapsed/Refractory Patients with Multiple Myeloma after Allogeneic Stem Cell Transplantation

Evgeny Klyuchnikov, MD, Ute-Marie von Pein, MD, Francis A. Ayuk, MD, Maximilian Christopeit, MD, Raissa Adjalle, MD, Andre van Randenborgh, MD, Christine Wolschke, MD, Nicolaus Kröger

Blood (2016) 128 (22): 3437.

https://doi.org/10.1182/blood.V128.22.3437.3437

Published: 2016

Journal Articles

Development of a Digital-PCR Assay for Screening and Quantitative Monitoring of Calreticulin (CALR) Type-2 Positive Patients with Myelofibrosis Following Allogeneic Stem Cell Transplantation

Boris Fehse, PhD, Anita Badbaran, Maximilian Christopeit, MD, Tim Aranyossy, Francis Ayuk, MD, Christine Wolschke, MD, Nicolaus Kroeger

Blood (2015) 126 (23): 1959.

https://doi.org/10.1182/blood.V126.23.1959.1959

Published: 2015

Journal Articles

Impact of Molecular Genetics on Disease-Free Survival in Myelofibrosis Patients Following Allogeneic Stem Cell Transplantation

Blood (2015) 126 (23): 352.

https://doi.org/10.1182/blood.V126.23.352.352

Published: 2015

Journal Articles

Impact of Minimal Residual Disease after Allografting Detected By JAK2V617F, MPL or Calreticulin in Myelofibrosis Patients

Nicolaus Kroeger, Anita Badbaran, Tatjana Zabelina, MD, Maximilian Christopeit, MD, Christine Wolschke, MD, Francis Ayuk, MD, Axel R. Zander, Professor, Haefaa Alchalby, MD, Ulrike Bacher, Ioanna N Triviai, PhD, Boris Fehse, PhD

Blood (2015) 126 (23): 4343.

https://doi.org/10.1182/blood.V126.23.4343.4343

Published: 2015

Journal Articles

New Allosteric Inhibitors of Mutant IDH1 in Acute Myeloid Leukemia

Blood (2015) 126 (23): 787.

https://doi.org/10.1182/blood.V126.23.787.787

Published: 2015

Journal Articles

Haploidentical Second Allogeneic Hematopoietic Stem Cell Transplantation for the Treatment of Acute Leukemia Relapse after First Allo-HSCT: A Retrospective Registry Analysis of 60 Patients on Behalf of the German Cooperative Transplant Group

Maximilian Christopeit, MD, Johanna Tischer, MD, Martin Bornhäuser, MD, Lutz Uharek, MD, Christian Pfrepper, Gerhard Behre, MD, Dietger Niederwieser, MD, Nicolaus Kröger, MD, Wolf Rösler, MD, Stefan A. Klein, Dietrich Beelen, MD, Andreas Hausmann, MD, Wolfgang Bethge, MD, Christoph Schmid, MD

Blood (2014) 124 (21): 2590.

https://doi.org/10.1182/blood.V124.21.2590.2590

Published: 2014

Journal Articles

Prognostic Impact of Physiological B-Cell Precursors (hematogones) in the Bone Marrow As Determined by Immunophenotyping in the Post-Transplant Period in Patients with AML

Ulrike Bacher, MD, Maximilian Christopeit, MD, Anneke Heiland, Mascha Binder, MD, Tatjana Zabelina, MD, Francis Ayuk, MD, Christiane Horn, Torsten Haferlach, MD, Carsten Bokemeyer, M.D., Nicolaus Kroeger, MD

Blood (2012) 120 (21): 1406.

https://doi.org/10.1182/blood.V120.21.1406.1406

Published: 2012

Journal Articles

Adult Patients with Hemophagocytic Lymphohistiocytosis (HLH) in Germany: A Retrospective Multicenter Case Study of 29 Patients

Thomas Schenk, MD, Georg Maschmeyer, MD, Frank Rothmann, MD, Thomas Weber, MD, Maximilian Christopeit, MD, Olaf Penack, MD, PhD, Daniela Goy, MD, Jens Panse, MD, Gritta Janka, MD, PhD, Andreas Hochhaus, MD, Paul La Rosee, MD

Blood (2012) 120 (21): 3271.

https://doi.org/10.1182/blood.V120.21.3271.3271

Published: 2012

NARROW

Impact of Allogeneic Hematopoietic Cell Transplantation Post-Sars-Cov-2 Infection: A Retrospective Analysis By the German Cooperative Transplant Study Group

Allogeneic Stem Cell Transplantation in Patients Aged ≥70 Years: Epidemiology, Outcomes, and Risk Factors Based on the German Registry for Stem Cell Transplantation (DRST)

Post-Transplant MRD Negativity on Day +100 Predicts Outcomes for Pre-Transplant Relapsed/Refractory AML Patients

Treatment of MDS, AML and CMML Relapse after Allogeneic Blood Stem Cell Transplantation with Azacitidine, Lenalidomide and Donor Lymphocyte Infusions - Final Results of the Prospective Azalena-Trial (NCT02472691)

Clinical Relevance of Somatic Mutations in Chronic Myelomonocytic Leukemia Undergoing Allogeneic Stem Cell Transplantation

High Cure Rate By Allogeneic Stem Cell Transplantation for Myelofibrosis Patients Aged 65 or Older

Clonal Evolution of Myelofibrosis Patients in Relapse after Allogeneic Stem Cell Transplantation Revealed By Whole Exome Sequencing

Allogeneic Stem Cell Transplantation As Salvage Therapy for First Relapse after Autografting in Multiple Myeloma Patients

Ruxolitinib for Myelofibrosis Patients Relapsing after Allogeneic Hematopoietic Transplantation

Ruxolitinib during Peritransplant Period for Myelofibrosis Patients Undergoing Allogeneic Stem Cell Transplantation Reduces Acute Graft-Versus-Host Disease

Impact of Pre-Transplant Ruxolitinib in Myelofibrosis Patients on Outcome after Allogeneic Stem Cell Transplantation

Impact of Donor-Recipient Histocompatibility and CMV-Mismatch on Outcome of Allogeneic Stem Cell Transplantation for AML and MDS: A Retrospective Registry Study of the German Stem Cell Transplant Registry (DRST) of the German Working Group for Blood and Marrow Transplantation (DAG-KBT)

Daratumumab Is an Effective and Safe Salvage Therapy in Relapsed/Refractory Patients with Multiple Myeloma after Allogeneic Stem Cell Transplantation

Development of a Digital-PCR Assay for Screening and Quantitative Monitoring of Calreticulin (CALR) Type-2 Positive Patients with Myelofibrosis Following Allogeneic Stem Cell Transplantation

Impact of Molecular Genetics on Disease-Free Survival in Myelofibrosis Patients Following Allogeneic Stem Cell Transplantation

Impact of Minimal Residual Disease after Allografting Detected By JAK2V617F, MPL or Calreticulin in Myelofibrosis Patients

New Allosteric Inhibitors of Mutant IDH1 in Acute Myeloid Leukemia

Haploidentical Second Allogeneic Hematopoietic Stem Cell Transplantation for the Treatment of Acute Leukemia Relapse after First Allo-HSCT: A Retrospective Registry Analysis of 60 Patients on Behalf of the German Cooperative Transplant Group

Prognostic Impact of Physiological B-Cell Precursors (hematogones) in the Bone Marrow As Determined by Immunophenotyping in the Post-Transplant Period in Patients with AML

Adult Patients with Hemophagocytic Lymphohistiocytosis (HLH) in Germany: A Retrospective Multicenter Case Study of 29 Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only